Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Feb;73(4):522–524. doi: 10.1038/bjc.1996.90

Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice.

L K Webster 1, E J Cosson 1, K H Stokes 1, M J Millward 1
PMCID: PMC2074445  PMID: 8595168

Abstract

The effect of the paclitaxel vehicle Cremophor on the pharmacokinetics of doxorubicin and doxorubicinol was studied in two groups of mice given intravenously either 2.5 ml kg-1 Cremophor or saline followed 5 min later by 10 mg kg-1 doxorubicin. In each group three mice were sacrificed at ten time points and doxorubicin and doxorubicinol were measured in plasma by high-performance liquid chromatography (HPLC). With Cremophor present, doxorubicin AUC increased from 1420+/-440 to 2770+/-660 ng h ml(-1) (P<0.05) and doxorubicinol AUC increased from 130+/-76 to 320+/-88 ng h ml(-1) (p<0.05). Neither the terminal elimination half-lives nor the doxorubicinol-doxorubicin AUC ratio changed in the presence of Cremophor, suggesting a lack of a direct effect on drug metabolism. The possibility exists the Cremophor may change the pharmacokinetics of both paclitaxel and other drugs given concurrently.

Full text

PDF
522

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bartlett N. L., Lum B. L., Fisher G. A., Brophy N. A., Ehsan M. N., Halsey J., Sikic B. I. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol. 1994 Apr;12(4):835–842. doi: 10.1200/JCO.1994.12.4.835. [DOI] [PubMed] [Google Scholar]
  2. Borst P., Schinkel A. H., Smit J. J., Wagenaar E., Van Deemter L., Smith A. J., Eijdems E. W., Baas F., Zaman G. J. Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. Pharmacol Ther. 1993 Nov;60(2):289–299. doi: 10.1016/0163-7258(93)90011-2. [DOI] [PubMed] [Google Scholar]
  3. Chervinsky D. S., Brecher M. L., Baker R. M., Hoelcle M. J., Tebbi C. K. Reversal of C1300 murine neuroblastoma multidrug resistance by cremophorEL, a solvent for cyclosporin A. Cancer Biother. 1993 Spring;8(1):67–75. doi: 10.1089/cbr.1993.8.67. [DOI] [PubMed] [Google Scholar]
  4. Friche E., Jensen P. B., Sehested M., Demant E. J., Nissen N. N. The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor. Cancer Commun. 1990;2(9):297–303. [PubMed] [Google Scholar]
  5. Gianni L., Kearns C. M., Giani A., Capri G., Viganó L., Lacatelli A., Bonadonna G., Egorin M. J. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol. 1995 Jan;13(1):180–190. doi: 10.1200/JCO.1995.13.1.180. [DOI] [PubMed] [Google Scholar]
  6. Kongshaug M., Cheng L. S., Moan J., Rimington C. Interaction of cremophor EL with human plasma. Int J Biochem. 1991;23(4):473–478. doi: 10.1016/0020-711x(91)90176-n. [DOI] [PubMed] [Google Scholar]
  7. Lum B. L., Kaubisch S., Yahanda A. M., Adler K. M., Jew L., Ehsan M. N., Brophy N. A., Halsey J., Gosland M. P., Sikic B. I. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol. 1992 Oct;10(10):1635–1642. doi: 10.1200/JCO.1992.10.10.1635. [DOI] [PubMed] [Google Scholar]
  8. Maessen P. A., Mross K. B., Pinedo H. M., van der Vijgh W. J. Improved method for the determination of 4'-epidoxorubicin and seven metabolites in plasma by high-performance liquid chromatography. J Chromatogr. 1987 Jul 3;417(2):339–346. doi: 10.1016/0378-4347(87)80127-5. [DOI] [PubMed] [Google Scholar]
  9. Sinicrope F. A., Dudeja P. K., Bissonnette B. M., Safa A. R., Brasitus T. A. Modulation of P-glycoprotein-mediated drug transport by alterations in lipid fluidity of rat liver canalicular membrane vesicles. J Biol Chem. 1992 Dec 15;267(35):24995–25002. [PubMed] [Google Scholar]
  10. Sonnichsen D. S., Relling M. V. Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet. 1994 Oct;27(4):256–269. doi: 10.2165/00003088-199427040-00002. [DOI] [PubMed] [Google Scholar]
  11. Speeg K. V., Maldonado A. L. Effect of the nonimmunosuppressive cyclosporin analog SDZ PSC-833 on colchicine and doxorubicin biliary secretion by the rat in vivo. Cancer Chemother Pharmacol. 1994;34(2):133–136. doi: 10.1007/BF00685930. [DOI] [PubMed] [Google Scholar]
  12. Sykes E., Woodburn K., Decker D., Kessel D. Effects of Cremophor EL on distribution of Taxol to serum lipoproteins. Br J Cancer. 1994 Sep;70(3):401–404. doi: 10.1038/bjc.1994.317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Webster L., Linsenmeyer M., Millward M., Morton C., Bishop J., Woodcock D. Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. J Natl Cancer Inst. 1993 Oct 20;85(20):1685–1690. doi: 10.1093/jnci/85.20.1685. [DOI] [PubMed] [Google Scholar]
  14. Woodcock D. M., Jefferson S., Linsenmeyer M. E., Crowther P. J., Chojnowski G. M., Williams B., Bertoncello I. Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res. 1990 Jul 15;50(14):4199–4203. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES